Abstract
Glioblastoma is the most common primary brain tumor and one of the most devastating cancers. High-grade glioma patients’ prognoses are very poor, usually with a median survival of less than one year. Maximal neurosurgical resection followed by external adjuvant radiation therapy and chemotherapy is the conventional treatment for newly diagnosed high-grade glioma. Resistance to cytotoxic agents remains the greatest barrier to the successful treatment of human cancer. The alkylating agents temozolomide (TMZ), carmustine (BCNU), and lomustine (CCNU), which readily cross the blood-brain barrier, are the major chemotherapeutic candidates in glioma treatment, but many patients do not benefit from these drugs due to inherent or acquired resistance. We recently developed a two-phase treatment (2PT) aimed at eliminating drug resistant glioma cells by a second-phase treatment with a low concentration of salinomycin. In this study, we evaluated 1) the effect of prolonged exposure of clinically useful TMZ, BCNU, and CCNU on glioma cells; and 2) the fate of surviving cells as well as their sensitivity to a low concentration of salinomycin. We found that prolonged treatment with TMZ, BCNU, and CCNU induces a senescent-like state in the resistant cells, and that they then can be partially eliminated with a second-phase treatment of a low concentration of salinomycin.
Keywords: Glioma, brain tumors, alkylating agents, temozolomide, BCNU, CCNU, salinomycin, senescence, relapse.
Clinical Cancer Drugs
Title:Low Concentration of Salinomycin Prevents Regrowth and Partially Depletes Human Glioma Cells Surviving High Concentrations of Alkylating Agents
Volume: 1
Author(s): Zahid M. Delwar, Avramidis Dimitrios, Åke Siden, Mabel Cruz, Kajsa Paulsson and Juan Sebastian Yakisich
Affiliation:
Keywords: Glioma, brain tumors, alkylating agents, temozolomide, BCNU, CCNU, salinomycin, senescence, relapse.
Abstract: Glioblastoma is the most common primary brain tumor and one of the most devastating cancers. High-grade glioma patients’ prognoses are very poor, usually with a median survival of less than one year. Maximal neurosurgical resection followed by external adjuvant radiation therapy and chemotherapy is the conventional treatment for newly diagnosed high-grade glioma. Resistance to cytotoxic agents remains the greatest barrier to the successful treatment of human cancer. The alkylating agents temozolomide (TMZ), carmustine (BCNU), and lomustine (CCNU), which readily cross the blood-brain barrier, are the major chemotherapeutic candidates in glioma treatment, but many patients do not benefit from these drugs due to inherent or acquired resistance. We recently developed a two-phase treatment (2PT) aimed at eliminating drug resistant glioma cells by a second-phase treatment with a low concentration of salinomycin. In this study, we evaluated 1) the effect of prolonged exposure of clinically useful TMZ, BCNU, and CCNU on glioma cells; and 2) the fate of surviving cells as well as their sensitivity to a low concentration of salinomycin. We found that prolonged treatment with TMZ, BCNU, and CCNU induces a senescent-like state in the resistant cells, and that they then can be partially eliminated with a second-phase treatment of a low concentration of salinomycin.
Export Options
About this article
Cite this article as:
Delwar M. Zahid, Dimitrios Avramidis, Siden Åke, Cruz Mabel, Paulsson Kajsa and Yakisich Sebastian Juan, Low Concentration of Salinomycin Prevents Regrowth and Partially Depletes Human Glioma Cells Surviving High Concentrations of Alkylating Agents, Clinical Cancer Drugs 2014; 1 (1) . https://dx.doi.org/10.2174/2212697X113019990002
DOI https://dx.doi.org/10.2174/2212697X113019990002 |
Print ISSN 2212-697X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-6988 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Receptor for AGEs (RAGE) as Mediator of NF-kB Pathway Activation in Neuroinflammation and Oxidative Stress
CNS & Neurological Disorders - Drug Targets Seizures and Anticonvulsants in Brain Tumours: Frequency, Mechanisms and Anti-Epileptic Management
Current Pharmaceutical Design Arachidonic Acid Induces the Migration of MDA-MB-231 Cells by Activating Raft-associated Leukotriene B4 Receptors
Clinical Cancer Drugs Natural Compounds as Inhibitors of SARS-CoV-2 Main Protease (3CLpro): A Molecular Docking and Simulation Approach to Combat COVID-19
Current Pharmaceutical Design RAGE: A Potential Target for Aβ-Mediated Cellular Perturbation in Alzheimers Disease
Current Molecular Medicine Saponins-uptake and Targeting Issues for Brain-specific Delivery for Enhanced Cell Death Induction in Glioblastoma
Letters in Drug Design & Discovery Biomimetic Mineralization of Tumor Targeted Ferromagnetic Iron Oxide Nanoparticles Used for Media of Magnetic Hyperthermia
Current Drug Delivery Resveratrol and Cancer Treatment: Is Hormesis a Yet Unsolved Matter?
Current Pharmaceutical Design Modulation of Immuno-biome during Radio-sensitization of Tumors by Glycolytic Inhibitors
Current Medicinal Chemistry The Inhibitor of Growth (ING) Gene Family: Potential Role in Cancer Therapy
Current Cancer Drug Targets Editorial [Hot Topic: Herpes Simplex Virus Type 1-Based Amplicons Vectors (Guest Editor: Alberto L. Epstein)]
Current Gene Therapy Clinical Development of Experimental Virus-Mediated Gene Therapy for Malignant Glioma
Anti-Cancer Agents in Medicinal Chemistry Biosafety of Gene Therapy Vectors Derived From Herpes Simplex Virus Type 1
Current Gene Therapy Targeting Cancer Stem Cells with Repurposed Drugs to Improve Current Therapies
Recent Patents on Anti-Cancer Drug Discovery A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastoma
Current Cancer Drug Targets Functions of S100 Proteins
Current Molecular Medicine Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects
Current Cancer Drug Targets Can Targeted Therapy be Successful without Metronomic Scheduling ?
Current Topics in Medicinal Chemistry The Pro-Survival Function of Akt Kinase can be Overridden or Altered to Contribute to Induction of Apoptosis
Current Cancer Drug Targets Malaria and artemisinin derivatives: an updated review
Mini-Reviews in Medicinal Chemistry